PA-NORDIC-PHARMA
14.3.2024 14:01:35 CET | Business Wire | Press release
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V. announced today that eminent oculoplastic surgeon John P. Fezza, MD will serve on its U.S. Medical Advisory Board (MAB) which includes Eric Donnenfeld, MD (New York), Richard Lindstrom, MD (Minnesota), Vance Thompson, MD (South Dakota), Preeya Gupta, MD (North Carolina), Paul Karpecki, OD (Kentucky), Lisa Nijm, MD, JD (Illinois), and Selina McGee, OD (Oklahoma).
Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel. The FDA-cleared, cross-linked hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
“The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair. “John will bring his unique perspective and understanding of the lacrimal drainage system to LACRIFILL’s novel treatment of dry eye disease.”
“I am thrilled to join this incredible Medical Advisory Board comprised of some of the most esteemed leaders in eyecare,” said John Fezza, MD. “They share a common vision of improving patient care, and understand the importance of treating dry eye disease. As the inventor of LACRIFILL Canalicular Gel, I believe we are launching a novel product that will change our approach to treating dry eyes.”
Nordic Pharma’s U.S. Medical Advisory Board brings together leading eye care providers from across the country, including ophthalmologists and optometrists in private practice and affiliated with major health systems. “John’s addition to our U.S. Medical Advisory Board provides historical and unique insights to this stellar group of optometry and ophthalmology leaders that will help set us up for a successful launch of LACRIFILL Canalicular Gel later this year,” said Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand.
Nordic Pharma is committed to engaging ophthalmologists and optometrists in the early launch stages of LACRIFILL Canalicular Gel. As part of the approach, members of the LACRIFILL team will be attending Vision Expo East, 2024 to share the benefits of LACRIFILL Canalicular Gel with optometrists and to discuss select pre-order opportunities.
“Optometry plays a crucial role in the management of dry eye disease as evident by prescribing the majority of medications to performing procedures like punctal occlusion,” said Paul M. Karpecki, O.D., FAAO. “The support for the profession shown by Nordic Pharma and the launch of the innovative product LACRIFILL Canalicular Gel, will go far in helping millions of patients suffering from dry eye disease.”
In addition to Dr. Fezza’s appointment, the LACRIFILL launch is further benefitting from Todd Love being hired as National Sales Director by Inizio Engage. “Todd comes to us with a strong legacy of leadership and camaraderie in the eye care industry for nearly 25 years,” said Jai G. Parekh, MD, MBA, Chief Commercial Officer of Nordic Pharma Eye Care U.S. “He is a ‘true natural’ and after years of experience at Alcon, Bausch & Lomb, and more recently, Sight Sciences, we look to him to help lead our initiatives in the field with our esteemed sales force. His acumen will be critical to our launch of LACRIFILL Canalicular Gel within the eye care community; I look forward to working closely with him.”
About John P. Fezza, M.D.
Dr. Fezza has been a member of the Center For Sight team since 1998 and specializes in cosmetic facial and laser surgery. He earned his bachelor’s degree from Duke University and received his medical education at New York Medical College, where he was President of the Alpha Omega Alpha honors society. He completed his internship in general surgery and residency in ophthalmology at Yale University and his two-year fellowship in oculofacial plastic surgery at Vanderbilt University. In addition, he completed a second fellowship in cosmetic surgery sponsored by the American Academy of Cosmetic Surgery. He has many years of subspecialty training focusing solely on eyelid, face and neck surgery, which he considers his passion.
Dr. Fezza has held many prestigious national positions in medical societies, including the position of Past President of the American Board of Facial Cosmetic Surgery, and Past Treasurer of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS). In 2016, he was honored with the ASOPRS Research Award and in 2019 he received the Henry Baylis Cosmetic Surgery Award for longstanding contributions in the field of cosmetic facial surgery.
A nationally recognized author and lecturer on cosmetic facial and laser surgery, Dr. Fezza is a member of the American Academy of Cosmetic Surgery, the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) and the American Board of Ophthalmology. Dr. Fezza is a well-respected pharmaceutical consultant, lecturer, and master trainer. He serves on advisory boards for Allergan, Revance Therapeutics and is involved as an investigator in FDA clinical trials. In addition, he is an ad hoc preceptor for ASOPRS fellows and was an Associate Clinical Professor in Oculoplastics at the University of South Florida. Dr. Fezza holds multiple patents for treatment of dry eye disease and medical devices for facial fillers.
About Nordic Group B.V.
Nordic Group B.V. is a privately owned, medium-size international pharmaceutical company which focuses on the development and commercialization of specialty products. Portfolio enhancement has been accomplished through targeted developments and focused acquisitions to build a foundation in Eye Care, Rheumatology and Women’s Health. Nordic Pharma has established deep roots throughout Europe, and more recently, expanded outside of Europe with increased acquisitions worldwide.
Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
About Nordic Pharma, Inc.
Nordic Pharma, Inc., subsidiary of Nordic Group B.V., is partnered with well-established global biopharmaceutical companies and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.
Safe Harbor
This press release contains forward-looking statements, including, without limitation, statements related to Nordic Group /Nordic Pharma’s business developments and the implementation of Nordic Group /Nordic Pharma’s strategic initiatives. Because these statements reflect Nordic Group /Nordic Pharma’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties that could cause actual developments and results to differ materially from Nordic Group /Nordic Pharma’s expectations. These factors include, but are not limited to, general market conditions, regulatory trends, changes in the financial conditions of third parties dealing with Nordic Group /Nordic Pharma, and other factors that could affect Nordic Group /Nordic Pharma’s business and financial performance. Nordic Group /Nordic Pharma does not assume any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314786115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Rises in France’s Top 85 Technology Services Ranking, Recording Significant Revenue Growth in the Market17.11.2026 07:30:00 CET | Press release
Global technology corporation FPT has ranked 85th among France’s digital services and technology consulting companies in the KPMG France and Numeum’s 2026 ranking, climbing 20 places year-on-year. The advancement follows approximately 50% revenue growth in France, reflecting the company’s expanding business scale and strengthening competitive position in the market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116291751/en/ The annual ranking covers 175 digital services and engineering and technology consulting companies based on their 2025 revenue generated in France. Published alongside the ranking, KPMG and Numeum’s Grand Angle ESN & ICT study highlights a broader industry shift, with generative and agentic AI emerging as major forces reshaping business models across the French technology services market. FPT’s growth in France has been built on long-standing relationships with major enterprises and its expanding rol
Kinaxis Brings Flagship Kinexions Conference to India, Showcasing Growing Market Momentum17.11.2026 02:30:00 CET | Press release
Inaugural event features leaders from Tata Consumer Products and Sun Pharma, highlighting India's growing role in global supply chain innovation Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain planning and orchestration, today opened its first-ever Kinexions India conference in Mumbai, highlighting the company's growing presence in the country and India's importance to its global innovation and customer delivery operations. With teams in Chennai and Bangalore supporting product development, engineering, professional services and customer success, India plays an important role in Kinaxis' global operations. The company continues to invest in research and development in India, strengthening its engineering and innovation capabilities to support the next generation of AI and supply chain orchestration technologies. "India plays an important role in how we innovate and support customers around the world," said Razat Gaurav, CEO of Kinaxis. "Bringing Kinexions here for
Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa16.11.2026 22:30:00 CET | Press release
European Commission approval based on data from Phase 3 STOP-HS1 and STOP-HS2, which showed that Povofortay® (povorcitinib) met the primary endpoint at Week 12 and delivered clinically meaningful, durable responses through Week 54 and was well tolerated 1,2 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Povofortay® (povorcitinib) 45 mg and 75 mg for the treatment of eligible adults with moderate to severe hidradenitis suppurativa (HS). “The European Commission approval of Povofortay marks an important milestone for Incyte, advancing a key growth driver for our business and bringing a new treatment option to people living with HS, a chronic and often debilitating disease,” 2,3 said Bill Meury, Chief Executive Officer, Incyte."As the first and only once-daily oral treatment approved in the European Union for eligible adults with moderate to severe HS, Povofortay gives physicians an important new option for their patients.” The approval is based on res
Moody’s Names Timothy Bhatt as Chief Information Officer16.11.2026 22:00:00 CET | Press release
Bhatt to lead enterprise technology strategy, AI deployment, and cyber and information security in Executive Leadership Team role Moody’s Corporation (NYSE: MCO) announced today that it has named Tim Bhatt to the newly created role of Chief Information Officer (CIO), effective December 7th, and that he will join the company’s Executive Leadership Team. Mr. Bhatt, who has served as Chief Technology Officer (CTO) of Moody’s Ratings since 2018, will also continue in that role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116893391/en/ Timothy Bhatt, Chief Information Officer, Moody's As CIO, Mr. Bhatt will lead Moody’s enterprise technology strategy, AI enablement, and information security, with responsibility for the company’s technology services and operations and cybersecurity teams. He will further modernize how Moody’s operates, bringing together human expertise, trusted data and AI agents to reimagine enterprise work
Lattice Extends Space Heritage with On-Orbit Milestone in TESAT Optical Communication Terminals16.11.2026 22:00:00 CET | Press release
Radiation-resilient Lattice Nexus FPGAs have operated as specified in TESAT optical communication terminals since 2025 Lattice Semiconductor (NASDAQ: LSCC), the low power programmable and platform firmware leader, today announced that its low power, radiation-resilient Lattice Nexus™ FPGAs have surpassed one year of on-orbit operation in TESAT optical communication terminals. Since launch, the FPGAs have delivered consistent performance in the demanding application of space-based laser communication at 10 Gbps, adding to Lattice’s space heritage of thousands of FPGAs launched to date. TESAT has flown optical communication terminals on GEO and LEO missions for more than a decade, supplying broadband constellations and institutional programs. For the redesign of its terminal electronics, Lattice Nexus FPGAs addressed TESAT’s requirements for radiation tolerance, low power, and board footprint. Built on 28 nm fully depleted silicon-on-insulator (FD-SOI) process technology, the Nexus platf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
